Abstract: Derivatives of GHL-Cu possessing greater resistance to proteolytic enzyme breakdown are disclosed. These derivatives can be taliored to increase their fat solubility, making them more useful in the formation of pharmaceutical creams and gels. Further, the derivatives of the present invention possess significant superoxide dismustase activity, making them useful for enhancing the wound-healing process in animals.
Abstract: A transparent dentifrice is provided wherein a cellulose derivative, typically CMC-Na, having a viscosity of 5 to 20 centipoises measured as 1% aqueous solution at 25.degree. C. is blended as a binding agent.
Abstract: The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), ##STR3## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR4## mannitol is excepted. A spergualin is useful as cancer control agents and immunomodulators.
Abstract: Vasopressin-like peptide whose structures have been modified by an alpha-methyl amino acid at the 4 or 7 position are set forth. These compounds have potent vasopressin antagonist activities.
Abstract: A synthetic gene encoding a 71-amino acid analog of human insulin-like grouwth factor (hIGF-I) has been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analog, IGF132, contains the first 17 amino acids of the B chain of human insulin in place of the first 16 amino acids of hIGF-I. The purified hybrid protein has high affinity for the type I IGF recepto (12 nM) yet has drastically reduced affinity for human serum carrier proteins (>1000 nM). This analog is 5 to 10 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells and is a more active growth factor in vivo due to its reduced affinity for serum carrier proteins. Other proteins with similar properties have also been constructed.
Type:
Grant
Filed:
September 21, 1987
Date of Patent:
October 24, 1989
Assignee:
Merck & Co., Inc.
Inventors:
Joy D. Applebaum, Marvin L. Bayne, Margaret A. Cascieri
Abstract: A phenyl derivative of pepstatin A, which is much more potent than pepstatin in inhibiting renin enzyme activity and has significantly greater selectivity for renin over pepsin inhibition than does pepstatin, which is useful in treating hypertension and congestive heart failure.
Type:
Grant
Filed:
October 1, 1987
Date of Patent:
October 17, 1989
Assignee:
Merck & Co., Inc.
Inventors:
Leeyuan Huang, Lawrence Koupal, Joseph Dunn, Jr., Jerrold M. Liesch, Otto Hensens, H. Boyd Woodruff
Abstract: A method is described for treating mammalian solid tumors by administering leukocyte-derived amplifiers of the immune system to tumor-bearing subjects. The amplifiers include Beta-1.0, Beta-1.1, Beta-1,12, TG, and TGG.
Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor-like polypeptide. In appropriate hosts these DNA sequences permit the production of human phospholipase inhibitor-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.
Type:
Grant
Filed:
March 15, 1985
Date of Patent:
October 17, 1989
Assignee:
Biogen, Inc.
Inventors:
Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin
Abstract: The tripeptide Arg-Lys-Glu, synthetized by conventional solution methods, and its salts display immunostimulating activity both on maturation of immature T cells and on T cell function.
Abstract: A method for the separation or purification of biopolymers comprises adsorbing the biopolymer on the surface of liquid oil droplets; and separating the adsorbed biopolymer from the oil droplets. The adsorbed biopolymer is separated from the oil droplets by mixing the droplets in an aqueous liquid, removing the lower aqueous phase and adding a fresh aqueous phase to the droplets, cooling the mixture to solidify and coalesce the oil and to cause it to release the adsorbed biopolymer to the fresh liquid, separating the fresh liquid and the biopolymer from the coalesced oil, separating the biopolymer from the fresh liquid.
Abstract: The invention relates to selected difluoro compounds of formulae Ia, Ib and Ic ( set out hereinafter) which are useful as inhibitors of human leukocyte elastase.
Abstract: Novel amino acid derivatives useful as a therapeutic agent are disclosed. These amino acid derivatives and the pharmaceutically acceptable salts thereof have a human renin inhibitory effect when administered orally and are useful for treatment of hypertension, especially renin-associated hypertension.
Abstract: This invention relates to a pharmaceuticals which contains thyroid hormones and improved method which extracts thyroid hormones from animal thyroid gland. The pharmaceuticals of this invention is used to treat senile cortical cataract. There are some effect of long term on other cataract except subcapsular cataract. The pharmaceuticals of this invention is applied in the form of eyedrops or injection.
Type:
Grant
Filed:
June 12, 1987
Date of Patent:
September 26, 1989
Assignee:
The Hospital Attached to Tianjin Academy of Medical Sciences
Abstract: Substantially pure, synthetic peptides corresponding to specific epitopic sites of various G-proteins and antibodies having binding affinity specifically for said epitopic sites have been prepared. Kit and method for identifying various G-proteins are also disclosed.
Type:
Grant
Filed:
September 25, 1987
Date of Patent:
September 26, 1989
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A method of treating osteoporosis, especially post-menopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.
Abstract: A method of increasing the modulus of elasticity of a biopolymer is disclosed, which comprises incorporating a hexameric unit of the formula--X--(APGVGV).sub.n --Y--whereinA is a peptide-forming residue of L-alanine;P is a peptide-forming residue of L-proline;G is a peptide-forming residue of glycine;V is a peptide-forming residue of L-valine;X is PGVGV, GVGV, VGV, GV, V, or a covalent bond;Y is APGVG, APGV, APG, AP, A, or a covalent bond; andn is an integer from 2 to 200, wherein said hexameric unit comprises at least 18 amino acid residues, into an elastomeric polypeptide chain.
Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.
Abstract: A composition which can bind heparin and promote cellular adhesion is provided which consists essentially of a polypeptide of the formula:arg-tyr-val-leu-pro-arg-This invention was made with Government support under contract number CA 29995 by the U.S.The Government has certain rights in the invention.
Abstract: A peptide that causes a suppression in protein synthesis by halting the translation of mRNA into protein, the peptide having a Stokes radius of less than 16 Angstroms, a molecular weight, determined by SDS-PAGE, of 17 kD (indicating that the peptide is a monomer) and an isoelectric point of 7.25. The peptide of the present invention may have therapeutic advantages in halting the proliferation of abnormal or excess protein,GOVERNMENT RIGHTSThis invention was made with United States Government support under Grant HL 24511-06 from the NIH. The United States Government has certain rights in this invention.